April 2024
1. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
   3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
   Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
   

   >> Share

   
   February 2024
2. BAYAS A, Menacher M, Lapa C, Tappe D, et al
   (18)fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitis.
   Lancet. 2024;403:665-666.
   

   >> Share

   
   December 2023
3. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
   Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
   Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
   

   >> Share

   
   March 2022
4. YEN HL, Sit THC, Brackman CJ, Chuk SSY, et al
   Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study.
   Lancet. 2022;399:1070-1078.
   

   >> Share

   
   August 2021
5. TZOLOS E, Bing R, Newby DE, Dweck MR, et al
   Categorising myocardial infarction with advanced cardiovascular imaging.
   Lancet. 2021;398:e9.
   

   >> Share

   
   May 2021
6. JANI AB, Schreibmann E, Goyal S, Halkar R, et al
   (18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
   Lancet. 2021 May 7. pii: S0140-6736(21)00581.
   

   >> Share

   
   February 2021
7. HOFMAN MS, Emmett L, Sandhu S, Iravani A, et al
   [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
   Lancet. 2021;397:797-804.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share